Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Shrugging off fears prompted by Chinese AI firm DeepSeek, Dutch computer chip equipment maker ASML on Wednesday reported ...

The FDA recently approved a bioengineered blood vessel, which becomes part of a patient’s body over time. It’s designed to ...

SEED Therapeutics Inc. has announced that its molecular glue therapy, ST-01156, has been granted Rare Pediatric Disease and ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Larry Robbins is an American hedge fund manager, philanthropist, and the founder, CEO, and portfolio manager of Glenview ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...